Partnership with Solve Scientific strengthens international sales as part of ongoing global expansion
Cambridge, UK, and Boston MA, USA, 03 November 2025: Nuclera, the biotechnology company accelerating drug discovery by providing rapid, easy access to functional proteins through its benchtop eProtein Discovery™ System, today announced that it has signed a partnership with Solve Scientific Australia, a life science research solutions provider. The agreement is the latest milestone in Nuclera’s global expansion, broadening access to eProtein Discovery to customers in Australia and New…
LONDON, UK & COPENHAGEN, Denmark – November 4, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Vicore Pharma Holding AB (STO: VICO) and is pleased to announce the placement of Katrine Husum as R&D Senior Project Director.Vicore Pharma is a clinical-stage pharmaceutical company focused on developing treatments for severe respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company is developing a new class of…
The October edition of our People Pathways newsletter is now available to read here!
Featuring:
✅ Preview of One Nucleus 2026 courses
✅ One Nucleus Jobs Board - Helping the Industry
✅ Online Training in Python Programming, Data Science, Networks, Machine Learning & AI
and some useful information...
Study published in ‘American Journal of Respiratory Cell and Molecular Biology’ validates Qureight’s deep-learning models and imaging platform beyond fibrotic lung disease, into new therapeutic areas for severe respiratory disease
Data demonstrate sensitive quantification of vascular remodelling and prediction of disease severity from routine CT scans, following surgical removal of chronic blood clots
Automated insights from application of Vascul8 model enabled identification of patients at high risk of residual pulmonary hypertension post-surgery which will reduce the need for routine post-…
A new blog has been published by Amsbio comparing the benefits of its CELLBANKER® range of cryopreservation solutions with ‘homebrew’ cryopreservation media.
Homebrew cryopreservation media are do-it-yourself solutions, commonly using a mixture of DMSO, a serum (such as FBS), and a basal growth medium. These mixtures are often favored because of their lower upfront cost or to meet specific lab needs, but the optimal formulation depends heavily on the cell line's sensitivity.
From academic research to GMP manufacturing, reproducibility, and reliability in cryopreservation are critical. While…
In the next two months, Creative Biolabs will host two webinars to outline the latest progress in research on CAR-T therapy against solid tumors in depth.One of the most challenging areas in immunotherapy, CAR-T therapy against solid tumors, is undergoing a series of technical developments. This series of lectures will address two key strategies: cytokine-sensing reprogramming and secretory target delivery systems for therapeutic molecules."Solid-tumor CAR-T is still one of the greatest challenges in CAR-T therapy," said the Head of Immuno-Oncology Research of Creative Biolabs. "With these…
Stevenage, UK, 23 October 2025 - NRG Therapeutics Ltd. (“NRG”), an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is pleased to announce expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.
NRG has identified a novel regulator of the mitochondrial permeability transition pore (mPTP) which is essential for pore opening and amenable to small molecule…
LONDON, UK - October 22, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer (CFO).Tristel plc is a global infection prevention company focused on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry.Anna Wasyl is a seasoned CFO with 20+ years of experience in multinational organizations, specializing in…
In the third quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations.We successfully placed executives for independent and VC & PE-backed firms, alongside large-cap and mid-cap public companies, filling critical roles across diverse disciplines worldwide. CEO/ C-suite/ BoardCEO, Diagnostic & laboratory services (PE-backed), FranceCEO, Small-molecule therapies (VC-backed), ItalyCEO, Bio-storage solutions (PE-backed), UKCEO, Cell & gene therapies (VC-backed), DenmarkChief Financial Officer, Medical…
BioBeat is joining the One Nucleus hub for life science innovation
Cambridge, UK: 23 October 2025
The exciting new chapter for BioBeat begins with One Nucleus! BioBeat, connecting entrepreneurs with biotech leaders, is joining the One Nucleus hub for life science innovation. One Nucleus supports companies of all sizes through networking, training and thought leadership.
For the past twelve years, BioBeat has energised the UK life sciences scene through delivering an informed conversational forum for ideas exchange, challenging norms and future scoping among leaders in the…